ID   OVSAYO
AC   CVCL_3115
DR   BTO; BTO:0003501
DR   Cell_Model_Passport; SIDM00464
DR   JCRB; JCRB1047
DR   JCRB; NIHS0300
DR   JCRB; NIHS0342
DR   LINCS_LDP; LCL-1527
DR   PRIDE; PXD003105
DR   Wikidata; Q54937037
RX   PubMed=9328139;
RX   PubMed=11121861;
RX   PubMed=15677628;
RX   PubMed=24023729;
RX   PubMed=26972028;
RX   PubMed=27141528;
CC   Population: Japanese.
CC   Doubling time: 88 hours (PubMed=9328139; PubMed=11121861).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Heterozygous (PubMed=24023729).
CC   Omics: GPI-anchored proteins analysis by proteomics.
CC   Discontinued: JCRB; NIHS0300; true.
CC   Discontinued: JCRB; NIHS0342; true.
CC   Derived from sampling site: Ovary.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   TH01: 7
ST   TPOX: 9,11
ST   vWA: 17,18
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 16
//
RX   PubMed=9328139; DOI=10.1038/bjc.1997.471;
RA   Yanagibashi T., Gorai I., Nakazawa T., Miyagi E., Hirahara F.,
RA   Kitamura H., Minaguchi H.;
RT   "Complexity of expression of the intermediate filaments of six new
RT   human ovarian carcinoma cell lines: new expression of cytokeratin
RT   20.";
RL   Br. J. Cancer 76:829-835(1997).
//
RX   PubMed=11121861; DOI=10.1016/S0304-3835(00)00605-4;
RA   Ohta I., Gorai I., Miyamoto Y., Yang J., Zheng J.-H., Kawata N.,
RA   Hirahara F., Shirotake S.;
RT   "Cyclophosphamide and 5-fluorouracil act synergistically in ovarian
RT   clear cell adenocarcinoma cells.";
RL   Cancer Lett. 162:39-48(2001).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=24023729; DOI=10.1371/journal.pone.0072162;
RA   Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M.,
RA   Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R.,
RA   Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.;
RT   "Type-specific cell line models for type-specific ovarian cancer
RT   research.";
RL   PLoS ONE 8:E72162-E72162(2013).
//
RX   PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Identification of glycosylphosphatidylinositol-anchored proteins and
RT   omega-sites using TiO2-based affinity purification followed by
RT   hydrogen fluoride treatment.";
RL   J. Proteomics 139:77-83(2016).
//
RX   PubMed=27141528; DOI=10.1016/j.dib.2016.04.001;
RA   Masuishi Y., Kimura Y., Arakawa N., Hirano H.;
RT   "Data for identification of GPI-anchored peptides and omega-sites in
RT   cancer cell lines.";
RL   Data Brief 7:1302-1305(2016).
//